The burgeoning popularity of semaglutide , initially for blood sugar control , is creating significant buzz within the UK , prompting a notable shift in peptide trends. Access these medications remains a complex challenge , with National Health Service provision currently limited and specialist practices offering treatment at a premium . Worries ar